Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT.

Seo Y, Aparici CM, Cooperberg MR, Konety BR, Hawkins RA.

J Nucl Med. 2010 Jan;51(1):31-6. doi: 10.2967/jnumed.109.067108. Epub 2009 Dec 15.

2.

Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system.

Seo Y, Wong KH, Sun M, Franc BL, Hawkins RA, Hasegawa BH.

J Nucl Med. 2005 May;46(5):868-77.

3.

Progress in SPECT/CT imaging of prostate cancer.

Seo Y, Franc BL, Hawkins RA, Wong KH, Hasegawa BH.

Technol Cancer Res Treat. 2006 Aug;5(4):329-36.

PMID:
16866563
4.

Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer.

Hardie AD, Rieter WJ, Bradshaw ML, Gordon LL, Young MA, Keane TE.

World J Urol. 2013 Dec;31(6):1327-32. doi: 10.1007/s00345-013-1079-2. Epub 2013 Apr 18.

PMID:
23595605
5.

Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer.

Ellis RJ, Kaminsky DA, Zhou EH, Fu P, Chen WD, Brelin A, Faulhaber PF, Bodner D.

Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):29-34. doi: 10.1016/j.ijrobp.2010.05.053. Epub 2010 Oct 18.

PMID:
20961696
6.

111-In-capromab pendetide imaging using hybrid-γ camera-computer tomography technology is not reliable in detecting seminal vesicle invasion in patients with prostate cancer.

Tsivian M, Wright T, Price M, Mouraviev V, Madden JF, Kimura M, Wong T, Polascik TJ.

Urol Oncol. 2012 Mar-Apr;30(2):150-4. doi: 10.1016/j.urolonc.2009.12.005. Epub 2010 Mar 2.

PMID:
20189846
7.

Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT.

Schuster DM, Savir-Baruch B, Nieh PT, Master VA, Halkar RK, Rossi PJ, Lewis MM, Nye JA, Yu W, Bowman FD, Goodman MM.

Radiology. 2011 Jun;259(3):852-61. doi: 10.1148/radiol.11102023. Epub 2011 Apr 14.

9.

Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland.

Mouraviev V, Madden JF, Broadwater G, Mayes JM, Burchette JL, Schneider F, Smith J, Tsivian M, Wong T, Polascik TJ.

J Urol. 2009 Sep;182(3):938-47. doi: 10.1016/j.juro.2009.05.047. Epub 2009 Jul 17.

PMID:
19616259
10.

Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging.

Wong WW, Schild SE, Vora SA, Ezzell GA, Nguyen BD, Ram PC, Roarke MC.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e423-9. doi: 10.1016/j.ijrobp.2011.01.048. Epub 2011 Apr 7.

PMID:
21477947
11.

Using vascular structure for CT-SPECT registration in the pelvis.

Hamilton RJ, Blend MJ, Pelizzari CA, Milliken BD, Vijayakumar S.

J Nucl Med. 1999 Feb;40(2):347-51.

12.

Capromab Pendetide imaging of prostate cancer.

Haseman MK, Rosenthal SA, Polascik TJ.

Cancer Biother Radiopharm. 2000 Apr;15(2):131-40. Review.

PMID:
10803318
13.

Detection and localization of carcinoma within the prostate using high resolution transrectal gamma imaging (TRGI) of monoclonal antibody directed at prostate specific membrane antigen (PSMA)--proof of concept and initial imaging results.

Franc BL, Cho SY, Rosenthal SA, Cui Y, Tsui B, Vandewalker KM, Holz AL, Poonamallee U, Pomper MG, James RB.

Eur J Radiol. 2013 Nov;82(11):1877-84. doi: 10.1016/j.ejrad.2013.07.025. Epub 2013 Aug 12.

PMID:
23993140
14.

Diagnostic performance of In-111 capromab pendetide SPECT/CT in localized and metastatic prostate cancer.

Rieter WJ, Keane TE, Ahlman MA, Ellis CT, Spicer KM, Gordon LL.

Clin Nucl Med. 2011 Oct;36(10):872-8. doi: 10.1097/RLU.0b013e318219ae29.

PMID:
21892036
15.
16.

Utilization of (111)In-Capromab pendetide SPECT-CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary in situ therapy.

Kimura M, Tsivian M, Mouraviev V, Mayes JM, Price MM, Bannister MC, Madden JF, Wong TZ, Polascik TJ.

Int J Urol. 2009 Dec;16(12):971-5. doi: 10.1111/j.1442-2042.2009.02413.x. Epub .

18.

Quantitative simultaneous 111In∕99mTc SPECT-CT of osteomyelitis.

Cervo M, Gerbaudo VH, Park MA, Moore SC.

Med Phys. 2013 Aug;40(8):082501. doi: 10.1118/1.4812421.

19.

Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients.

Polascik TJ, Manyak MJ, Haseman MK, Gurganus RT, Rogers B, Maguire RT, Partin AW.

Cancer. 1999 Apr 1;85(7):1586-92.

PMID:
10193950
20.

Image quantification for radiation dose calculations--limitations and uncertainties.

Pereira JM, Stabin MG, Lima FR, Guimarães MI, Forrester JW.

Health Phys. 2010 Nov;99(5):688-701. doi: 10.1097/HP.0b013e3181e28cdb.

Items per page

Supplemental Content

Write to the Help Desk